22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company's products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryCannabis
SectorMedical
CIKN/A
Phone+1-716-2701523
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees79
Next Earnings Date2/27/2019 (Estimated)
OptionableOptionable
22nd Century Group (NYSEAMERICAN:XXII) Frequently Asked Questions
What is 22nd Century Group's stock symbol?
22nd Century Group trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XXII."
How were 22nd Century Group's earnings last quarter?
22nd Century Group Inc (NYSEAMERICAN:XXII) issued its quarterly earnings data on Wednesday, November, 7th. The biotechnology company reported $0.04 earnings per share for the quarter. The biotechnology company earned $6.26 million during the quarter. View 22nd Century Group's Earnings History.
When is 22nd Century Group's next earnings date?
Has 22nd Century Group been receiving favorable news coverage?
Media stories about XXII stock have trended somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. 22nd Century Group earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting 22nd Century Group?
22nd Century Group saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 21,367,079 shares, an increase of 25.8% from the January 15th total of 16,984,645 shares. Based on an average daily trading volume, of 2,310,685 shares, the short-interest ratio is presently 9.2 days. Currently, 19.6% of the shares of the company are sold short. View 22nd Century Group's Current Options Chain.
Who are some of 22nd Century Group's key competitors?
Some companies that are related to 22nd Century Group include Concordia International (CXR), Theratechnologies (TH), Resverlogix (RVX), Mesoblast (MSB), Emerald Health Therapeutics (EMH), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), IMV (IMV), Enochian Biosciences (ENOB), Kodiak Sciences (KOD), IMV (IMV), Monash IVF Group (MVF), ProMetic Life Sciences (PLI) and CorMedix (CRMD).
What other stocks do shareholders of 22nd Century Group own?
Who are 22nd Century Group's key executives?
22nd Century Group's management team includes the folowing people:
- Mr. Henry Sicignano III, Pres, CEO & Director (Age 51)
- Mr. John T. Brodfuehrer, CFO & Treasurer (Age 61)
- Mr. Thomas L. James Esq., VP, Gen. Counsel & Sec. (Age 60)
- James Vail, Director of Communications
- Dr. Paul J. Rushton, VP of Plant Biotechnology (Age 56)
Who are 22nd Century Group's major shareholders?
22nd Century Group's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.49%), ETF Managers Group LLC (3.67%), Northern Trust Corp (1.04%), Geode Capital Management LLC (0.94%), Bank of New York Mellon Corp (0.33%) and NJ State Employees Deferred Compensation Plan (0.13%). Company insiders that own 22nd Century Group stock include Michael Robert Moynihan and Thomas L James. View Institutional Ownership Trends for 22nd Century Group.
Which major investors are selling 22nd Century Group stock?
XXII stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Northern Trust Corp, NJ State Employees Deferred Compensation Plan and National Asset Management Inc.. View Insider Buying and Selling for 22nd Century Group.
Which major investors are buying 22nd Century Group stock?
XXII stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Geode Capital Management LLC, BlackRock Inc., Bank of New York Mellon Corp, Advisory Services Network LLC, MetLife Investment Advisors LLC, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. and Rhumbline Advisers. View Insider Buying and Selling for 22nd Century Group.
How do I buy shares of 22nd Century Group?
Shares of XXII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is 22nd Century Group's stock price today?
One share of XXII stock can currently be purchased for approximately $2.54.
How big of a company is 22nd Century Group?
22nd Century Group has a market capitalization of $315.98 million. 22nd Century Group employs 79 workers across the globe.
What is 22nd Century Group's official website?
How can I contact 22nd Century Group?
22nd Century Group's mailing address is 9530 Main St, CLARENCE, NY 14031-1915, United States. The biotechnology company can be reached via phone at +1-716-2701523.
MarketBeat Community Rating for 22nd Century Group (NYSEAMERICAN XXII)
MarketBeat's community ratings are surveys of what our community members think about 22nd Century Group and other stocks. Vote "Outperform" if you believe XXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
